All News

Researchers found an overall response rate of 29.8% in patients treated with 177Lu-PSMA-617, compared to a 1.7% partial response in the standard of care only arm.

The investigators found that population-based cancer registries showed a 10.2% decline in real-time electronic pathology reports in 2020 compared to 2019.

Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

Umbralisib was granted accelerated approval by the FDA for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Edwin Gump, PhD, vice president of the Small Molecules Department at US Pharmacopeia (USP), discusses USP’s reference standards that support the analysis and monitoring of nitrosamine impurities in the drug supply chain.

Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.

The results from the first phase 3 SURPASS trials showed promising results with tirzepatide in patients with type 2 diabetes.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

Pharmacists should assess patient comorbidities, symptoms, and history to ensure the selection of the most appropriate migraine medication.

The use of high throughput technologies has revolutionized the understanding of the cancer genome.

Novo Nordisk presented data for 2 mg dose of Ozempic at the 81st Annual Scientific Sessions of the American Diabetes Association.

This study was among the first to display the adverse relationship in younger adults, according to the letter.

Pharmacists now play an integral role as medication experts of the health care team, ensuring optimal medication use and improving patient health outcomes.

Orelabrutinib is a highly selective Bruton's tyrosine kinase inhibitor designed to target B-cell lymphomas and autoimmune indications.

The DARE-19 clinical trial explores the use of SGLT2 inhibitors for patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease, and COVID-19.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Hypertension is a risk factor for cognitive decline and dementia in older adults.

Trilaciclib (Cosela) is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Study presented at the American Diabetes Association (ADA) 81st Scientific Sessions shows meaningful outcomes for people with diabetes who use the FreeStyle Libre system.

Data show diabetes patients not taking medication experienced longer hospitalization and recovery from the coronavirus.

Too much bile acids can lead to damage in the cell membranes and can cause cell death and inflammation.

Initial data show that children presented with higher acuity in 2020 compared to the previous year.

Studies show that an increased life expectancy is attributable to growth in gross domestic product, increases in the average years of school, and other social factors.

Antiviral medications, including Acyclovir, famciclovir, and valacyclovir, are effective if taken as soon as the diagnosis and can shorten the duration of the infection while improving symptoms.

Novel treatments and recent data about new drugs were presented at the first conference of Advanced Topics for Oncology Pharmacy Professionals (ATOPP).

June 27 is National HIV Testing Day, so Pharmacy Times interviewed Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, on his perspective on the critical role of testing all sexually active individuals who may be at risk for HIV.

The small-molecule inhibitors of the SOX 11 oncogene showed promise both as single agents and in combination with ibrutinib.